Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

NCT04404283 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

239

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Large B-cell Lymphoma

Interventions

DRUG: Brentuximab vedotin
DRUG: Rituximab
DRUG: Lenalidomide
OTHER: Placebo

Sponsor

Seagen, a wholly owned subsidiary of Pfizer